Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry
-
Published:2004-03-01
Issue:5
Volume:22
Page:838-845
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Michalkiewicz E.1, Sandrini R.1, Figueiredo B.1, Miranda E.C.M.1, Caran E.1, Oliveira-Filho A.G.1, Marques R.1, Pianovski M.A.D.1, Lacerda L.1, Cristofani L.M.1, Jenkins J.1, Rodriguez-Galindo C.1, Ribeiro R.C.1
Affiliation:
1. From the Oncologic Pediatric Surgery Division, Erasto Gaertner Hospital, Liga Paranaense de Combate ao CÂncer, Curitiba; Division of Pediatric Endocrinology and Center for Molecular Genetics and Childhood Cancer Research (CEGEMPAC), Hospital de Clinicas, Federal University of Paraná, Curitiba, Paraná; the Biostatistics Division, Hemocentro, and The Instituto Domingos Boldrini, Universidade Estadual de Campinas, Campinas; Department of Pediatric Oncology, Universidade Federal de São Paulo, Escola Paulista...
Abstract
Purpose We created a registry for pediatric adrenocortical tumors (ACTs), which are rare and are not well characterized. We provide a descriptive analysis of 254 patients registered on the International Pediatric Adrenocortical Tumor Registry. Patients and Methods Between January 1990 and December 2001, 254 patients younger than 20 years of age with newly diagnosed or previously treated ACTs were registered. A histologic diagnosis of ACT was required, although central review was not mandatory. Follow-up information was periodically requested from the referring physician. Treatment was chosen by the primary physician. Results The overall female-male ratio was 1.6:1, but it varied widely among age groups. The most common presenting sign (84.2%) was virilization. Cushing's syndrome without virilization was uncommon (5.5%). Tumors were completely resected in 83% of patients. Patients with disseminated or residual disease received mitotane, cisplatin, etoposide, and/or doxorubicin, and rarely, radiation therapy. At a median follow-up of 2 years and 5 months, 157 patients (61.8%) survived without evidence of disease and 97 patients (38.2%) had died. The 5-year event-free survival estimate was 54.2% (95% CI, 48.2% to 60.2%). In a multivariate analysis, disease stage, presenting signs of endocrine dysfunction, and age were independently associated with prognosis. Conclusion Childhood ACTs occur predominantly in females and almost always causes clinical signs. Complete resection is required for cure. Residual or metastatic disease carries a poor prognosis. Our results demonstrate the feasibility of a disease-specific database for obtaining meaningful clinical and outcome information.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference33 articles.
1. Ribeiro RC, Michalkiewicz EL: Adrenocortical tumors in children, in Raghavan D, Brecher ML, Johnson DH, et al (eds): Textbook of Uncommon Cancer (ed 2) . New York, NY, John Wiley & Sons, pp 611,1999-620 2. Lefevre M, Gerard-Marchant R, Chaussain JL, et al: Adrenal cortical carcinoma in children: 42 patients treated from 1958 to 1980 at Villejuif, in Humphrey GB, Grindey GB, Dehner LP, et al (eds): Adrenal and Endocrine Tumors in Children . Boston, MA, Martinus Nijhoff, pp 265,1983-276 3. Adrenocortical carcinoma in children: a study of 40 cases. 4. Sandrini R, Ribeiro RC, DeLacerda L: Childhood adrenocortical tumors. J Clin Endocrinol Metab 82:2027,1997-2031, 5. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma
Cited by
414 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|